-
Thematic Analysis
NewIT Services Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Companies scoring well in the cloud, data analytics, and future of work themes lead the thematic screen of GlobalData’s IT services sector scorecard. This is dominated by the global IT services giants Accenture, IBM, and Infosys, closely followed by Capgemini and Tata Consultancy Services (TCS). Indian heritage vendors occupy half of the top 10 vendor positions, suggesting they are successfully adapting their strategies to the long-term concern of a declining cost advantage versus their US and European peers.
-
Analyst Opinions
NewNorth America Energy Transition by Key Sectors and Companies Driving Development
North America’s energy transition is continuing to gather pace, with a combination of technological development and favorable policy incentives driving substantial growth across renewables, hydrogen and CCUS sectors. Technologies such as electric vehicles and renewable fuels are also experiencing increasing adoption albeit at a slower rate. Despite the current dominance of natural gas within North America’s generation mix, a rapid build-out of solar PV and wind capacity will boost renewable generation so that it will contribute 55% of total generation...
-
Thematic Analysis
NewDigital Twins – Thematic Intelligence
Digital Twins Thematic Report Overview Digital twins are digital representations of physical assets, systems, people, or processes. They help in detecting, preventing, predicting, and optimizing the physical environment using artificial intelligence (AI), real-time analytics, visualization, and simulation tools. Digital twins can provide short and long-term efficiency and productivity gains by dynamically integrating data and information about an asset, part, process, or system’s lifecycle. They are a data resource that can improve asset design, understand an existing asset’s condition, verify the...
-
Company Insights
NewKingfisher – Digital Transformation Strategies
Kingfisher Digital Transformation Strategies Overview Kingfisher has been focusing on using artificial intelligence, cloud-based mobile applications, big data, and augmented reality to digitally transform its operations. The annual ICT spending of Kingfisher was estimated at $369.9 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Kingfisher sells home improvement products and offers home improvement services to consumers and trade professionals in eight European countries. It operates under the B&Q,...
-
Thematic Analysis
Cloud Computing – Thematic Intelligence
Cloud Computing Thematic Report Overview The cloud services sector competes to provide the best artificial intelligence (AI) platforms and services, partly catalyzed by the emergence of generative AI. AI is now central to the cloud services market, from developing custom chips and supporting workloads and providing the models and tools necessary to develop AI-enabled solutions. The Cloud Computing  thematic intelligence report provides an overview of the cloud computing theme. It identifies the key trends impacting the growth of the theme...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Breast Cancer Drug Details: Atezolizumab (Tecentriq) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sabatolimab in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sabatolimab in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sabatolimab in Myelofibrosis Drug Details: Sabatolimab is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Chronic Lymphocytic Leukemia (CLL) Drug Details: Atezolizumab (Tecentriq)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...